
Carlos Henrique Barrios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/488871/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Research and Treatment, 2022, 191, 565-576.	2.5	32
2	Global challenges in breast cancer detection and treatment. Breast, 2022, 62, S3-S6.	2.2	43
3	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology, 2022, 40, 438-448.	1.6	35
4	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). Cancer Research, 2022, 82, PD13-01-PD13-01.	0.9	1
5	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	10.7	4
6	Conditional survival and longâ€ŧerm efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	4.1	103
7	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer, 2022, 166, 185-201.	2.8	13
8	Abstract 5271: Correlative analysis of RNA biomarkers for adjuvant capecitabine benefit in the CIBOMA/2004-01phase III clinical trial of triple negative breast cancer patients. Cancer Research, 2022, 82, 5271-5271.	0.9	0
9	Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology, 2022, 40, 2946-2956.	1.6	46
10	Implications of the PEARL trial from the low- to middle-income countries' perspectives. European Journal of Cancer, 2022, 173, 30-32.	2.8	0
11	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	2.4	140
12	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1.	5.2	331
13	Atezolizumab and <i>nab</i> -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal of the National Cancer Institute, 2021, 113, 1005-1016.	6.3	171
14	Is Independent Clinical Research Possible in Low- and Middle-Income Countries? A Roadmap to Address Persistent and New Barriers and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 221-230.	3.8	3
15	High Rate of Studies with Level 1 and 2 Evidence among the 100 Most Cited Articles in Lumbar Spinal Stenosis. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2021, 82, 453-462.	0.8	0
16	Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). JCO Global Oncology, 2021, 7, 649-658.	1.8	19
17	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology, 2021, 39, 1349-1359.	1.6	147
18	Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology, 2021, 7, 474-485.	1.8	2

#	Article	IF	CITATIONS
19	Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial Journal of Clinical Oncology, 2021, 39, 4553-4553.	1.6	16
20	The tumor microenvironment (TME) and atezolizumab + <i>nab</i> -paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130 Journal of Clinical Oncology, 2021, 39, 1006-1006.	1.6	33
21	Sociodemographic and clinicopathologic features of elderly breast cancer patients in Brazil: A sub-analysis of AMAZONA III study (GBCAM 0115) Journal of Clinical Oncology, 2021, 39, e12603-e12603.	1.6	1
22	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. Journal of Thoracic Oncology, 2021, 16, 1872-1882.	1.1	85
23	Open questions and controversies in the systemic treatment of breast cancer. Current Opinion in Oncology, 2021, Publish Ahead of Print, 591-596.	2.4	1
24	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. Npj Breast Cancer, 2021, 7, 120.	5.2	9
25	Cardiorespiratory function of patients undergoing surgical correction of Scheuermann's hyperkyphosis. Scientific Reports, 2021, 11, 20138.	3.3	2
26	Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncology, The, 2021, 22, e474-e487.	10.7	38
27	Differences in Adiposity Profile and Body Fat Distribution between Forwards and Backs in Sub-Elite Spanish Female Rugby Union Players. Journal of Clinical Medicine, 2021, 10, 5713.	2.4	6
28	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of Clinical Oncology, 2020, 38, 203-213.	1.6	87
29	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	10.7	161
30	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 44-59.	10.7	826
31	Orthopedic treatment and early weight-bearing for bimalleolar ankle fractures in elderly patients: Quality of life and complications. Injury, 2020, 51, 548-553.	1.7	11
32	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports, 2020, 10, 11203.	3.3	6
33	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, The, 2020, 396, 1817-1828.	13.7	992
34	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet, The, 2020, 396, 1090-1100.	13.7	625
35	Reply to Y. Usui et al. Journal of Clinical Oncology, 2020, 38, 2113-2114.	1.6	0
36	Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer. JCO Global Oncology, 2020, 6, 307-312.	1.8	5

#	Article	IF	CITATIONS
37	Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e511-e515.	2.6	10
38	Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339.	27.0	959
39	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. Journal of the National Cancer Institute, 2019, 111, 86-94.	6.3	73
40	Severe hyperkyphosis reduces the aerobic capacity and maximal exercise tolerance in patients with Scheuermann disease. Spine Journal, 2019, 19, 330-338.	1.3	4
41	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125, 3974-3984.	4.1	67
42	Safety of trastuzumab emtansine (T-DM1)Âin patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. European Journal of Cancer, 2019, 109, 92-102.	2.8	73
43	A study of reproducibility of kinesiology tape applications: review, reliability and validity. BMC Musculoskeletal Disorders, 2019, 20, 153.	1.9	8
44	Radiological Evaluation Does Not Reflect the Clinical Outcome After Surgery in Unstable Thoracolumbar and Lumbar Type A Fractures Without Neurological Symptoms. Clinical Spine Surgery, 2019, 32, E117-E125.	1.3	8
45	PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114). BMC Cancer, 2019, 19, 5.	2.6	17
46	The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer, 2018, 119, 7-13.	2.0	43
47	The effect of adhesives on inflammatory immuneâ€markers during renal injury healing. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2018, 106, 1444-1455.	3.4	0
48	Stage III Non–Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort. Journal of Global Oncology, 2018, 4, 1-11.	0.5	3
49	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018, 379, 2108-2121.	27.0	3,097
50	Lung cancer in Brazil. Jornal Brasileiro De Pneumologia, 2018, 44, 55-64.	0.7	71
51	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Journal of Clinical Oncology, 2017, 35, 141-148.	1.6	327
52	Women's acute anxiety variations before and after epidural anesthesia for childbirth. Journal of Psychosomatic Obstetrics and Gynaecology, 2017, 38, 152-158.	2.1	7
53	Cardiorespiratory Function Does Not Improve 2 Years After Posterior Surgical Correction of Adolescent Idiopathic Scoliosis. Spine, 2017, 42, 1391-1397.	2.0	13
54	Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System. Journal of Global Oncology, 2017, 3, 201-207.	0.5	20

#	Article	IF	CITATIONS
55	Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review. Revista Brasileira De Ginecologia E Obstetricia, 2016, 38, 615-622.	0.8	10
56	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2â^' advanced breast cancer. Cancer Treatment Reviews, 2015, 41, 94-104.	7.7	22
57	Polyurethane on titanium unconstrained disc arthroplasty versus anterior discectomy and fusion for the treatment of cervical disc disease: a review of level l–II randomized clinical trials including clinical outcomes. European Spine Journal, 2015, 24, 2735-2745.	2.2	14
58	Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 126-133.	2.5	69
59	Abdominal muscle EMG-activity during bridge exercises on stable and unstable surfaces. Physical Therapy in Sport, 2014, 15, 162-168.	1.9	69
60	Influence of hypotension and nerve root section on the ability to mobilize the spinal cord during spine surgery. An experimental study in a pig model. Spine Journal, 2014, 14, 1300-1307.	1.3	2
61	Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2. Journal of Clinical Oncology, 2013, 31, 2849-2853.	1.6	216
62	Endocrine resistance in advanced breast cancer: current evidence and future directions. Breast Cancer Management, 2012, 1, 305-314.	0.2	1
63	A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial Journal of Clinical Oncology, 2012, 30, 549-549.	1.6	1
64	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, The, 2007, 369, 1519-1527.	13.7	1,185